| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About | |
Study Of SB-715992 In Subjects With Breast Cancer
This study is currently recruiting patients.
| Sponsored by: | GlaxoSmithKline |
|---|---|
| Information provided by: | GlaxoSmithKline |
Purpose
The purpose of this research study is to find how breast cancer responds to the investigational drug, SB-715992. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for research use only. In particular, this study will try is to find the answers to the following research questions: 1. Does breast cancer respond to SB-715992? 2. What are the side effects of SB-715992? 3. How much SB-715992 is in the blood at specific times after it is taken?
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Breast Cancer |
Drug: SB715992 |
Phase II |
MedlinePlus related topics: Breast Cancer
Genetics Home Reference related topics: breast cancer
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Uncontrolled, Single Group Assignment, Efficacy Study
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Exclusion criteria:
Location
and Contact
Information
More Information
 | ||||||||||||||
| U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
| National Institutes of Health, Department of Health & Human Services | ||||||||||||||
| Copyright, Privacy, Accessibility, Freedom of Information Act | ||||||||||||||